These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 27908728)

  • 1. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22).
    De Weer A; Poppe B; Cauwelier B; Carlier A; Dierick J; Verhasselt B; Philippé J; Van Roy N; Speleman F
    BMC Cancer; 2008 Jul; 8():193. PubMed ID: 18613965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.
    Paquette RL; Nicoll J; Chalukya M; Elashoff D; Shah NP; Sawyers C; Spiteri E; Nanjangud G; Rao PN
    Cancer Genet; 2011 Jul; 204(7):392-7. PubMed ID: 21872826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study of genes involved in chronic myeloid leukemia with t (3; 21) (q26; q22) in blastic crisis].
    Liu XP; Zhang MR; Dai Y; Zhang L; Li R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):310-3. PubMed ID: 16875579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a myeloid leukaemia cell line (Kasumi-4) with t(9;22;11)(q34;q11;q13), inv(3)(q21q26) and the EVI1 gene activation from a patient with chronic myelogenous leukaemia in blast crisis.
    Asou H; Eguchi M; Suzukawa K; Morishita K; Tanaka K; Date M; Hamamoto K; Kamada N
    Br J Haematol; 1996 Apr; 93(1):68-74. PubMed ID: 8611478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EVI1 expression associated with a 3q26 anomaly in a leukemia cell line derived from the blast crisis of chronic myeloid leukemia.
    Ohyashiki K; Ohyashiki JH; Fujieda H; Shimamoto T; Kawakubo K; Nakazawa S; Suzukawa K; Morishita K; Toyama K
    Leukemia; 1994 Dec; 8(12):2169-73. PubMed ID: 7808006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M
    Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphia-positive chronic myelogenous leukemia.
    Henzan H; Yoshimoto G; Okeda A; Nagasaki Y; Hirano G; Takase K; Tanimoto T; Miyamoto T; Fukuda T; Nagafuji K; Harada M
    Ann Hematol; 2004 Dec; 83(12):784-8. PubMed ID: 15322764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular biology of chronic myeloid leukaemia.
    Melo JV
    Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
    Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
    Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia.
    Kuila N; Nayak KB; Halder A; Agatheeswaran S; Biswas G; Biswas S; Pattnayak NC; Chakraborty S
    Leuk Lymphoma; 2017 Aug; 58(8):1941-1947. PubMed ID: 27967290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
    Jamieson CH; Ailles LE; Dylla SJ; Muijtjens M; Jones C; Zehnder JL; Gotlib J; Li K; Manz MG; Keating A; Sawyers CL; Weissman IL
    N Engl J Med; 2004 Aug; 351(7):657-67. PubMed ID: 15306667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
    Cuenco GM; Ren R
    Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics of childhood leukemia with EVI1 gene and BCR/ABL gene co-expression].
    Jiang M; Li XQ; Hu D; Zhang ZQ; Yang YY; Bai LC; Jin RM
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 May; 16(5):489-93. PubMed ID: 24856998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
    Cuenco GM; Ren R
    Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
    Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
    Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.